Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heat treated zoster vaccine
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The heat-treated zoster vaccine (V212) is an investigational inactivated viral vaccine developed by Merck for the prevention of herpes zoster (shingles) and its complications in immunocompromised individuals, such as recipients of autologous hematopoietic stem cell transplants (auto-HSCT) and patients with solid tumors undergoing chemotherapy. Based on the Oka/Merck strain of the varicella-zoster virus (VZV), the vaccine is inactivated by heat treatment to render it non-replicating, making it a safer alternative to the live-attenuated vaccine (Zostavax) which is contraindicated in immunocompromised patients. Although V212 demonstrated efficacy and safety in Phase III clinical trials, Merck discontinued its development in 2019 due to changes in the herpes zoster vaccine landscape, primarily driven by the approval and widespread adoption of GSK's highly effective recombinant adjuvanted vaccine, Shingrix.
- Other names
- inactivated varicella-zoster virus vaccineZVINZVHTinactivated varicella-zoster vaccineheat-treated varicella-zoster virus vaccine
Beyond the preview
Go deeper on heat treated zoster vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heat treated zoster vaccine.